{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:46:37Z","timestamp":1795146397926,"version":"4.10.3"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Exotropia and myopia are commonly coexistent. However, evidence is limited regarding atropine interventions for myopia control in children with myopia and intermittent exotropia (IXT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of 0.01% atropine eye drops on myopia progression, exotropia conditions, and binocular vision in individuals with myopia and IXT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This placebo-controlled, double-masked, randomized clinical trial was conducted from December 2020 to September 2023. Children aged 6 to 12 years with basic-type IXT and myopia of \u22120.50 to \u22126.00 diopters (D) after cycloplegic refraction in both eyes were enrolled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were randomly assigned in a 2:1 ratio to 0.01% atropine or placebo eye drops administered in both eyes once at night for 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was change in cycloplegic spherical equivalent from baseline at 1 year. Secondary outcomes included change in axial length (AL), accommodative amplitude (AA), exotropia conditions, and binocular vision at 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 323 screened participants, 300 children (mean [SD] age, 9.1 [1.6] years; 152 male [50.7%]) were included in this study. A total of 200 children (66.7%) were in the atropine group, and 100 (33.3%) were in the placebo group. At 1 year, the 0.01% atropine group had slower spherical equivalent progression (\u22120.51 D vs \u22120.75 D; difference\u2009=\u20090.24 D; 95% CI, 0.11-0.37 D; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and AL elongation (0.31 mm vs 0.42 mm; difference\u2009=\u2009\u22120.11 mm; 95% CI, \u22120.17 to \u22120.06 mm; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) than the placebo group. The mean AA change was \u22123.06 D vs 0.12 D (difference\u2009=\u2009\u22123.18 D; 95% CI, \u22123.92 to \u22122.44 D; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) in the atropine and placebo groups, respectively. The 0.01% atropine group had a decrease in near magnitude of exodeviation whereas the placebo group had an increase (\u22121.25 prism diopters [PD] vs 0.74 PD; difference\u2009=\u2009\u22121.99 PD; 95% CI, \u22123.79 to \u22120.19 PD; <jats:italic>P<\/jats:italic>\u2009=\u2009.03). In the atropine vs placebo group, respectively, the incidence of study drug-related photophobia was 6.0% (12 of 200 participants) vs 8.0% (8 of 100 participants; difference\u2009=\u2009\u22122.0%; 95% CI, \u22129.4% to 3.7%; <jats:italic>P<\/jats:italic>\u2009=\u2009.51) and for blurred near vision was 6.0% (12 of 200 participants) vs 7.0% (7 of 100 participants) (difference\u2009=\u2009\u22121.0%; 95% CI, \u22128.2% to 4.5%; <jats:italic>P<\/jats:italic>\u2009=\u2009.74).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this randomized clinical trial support use of 0.01% atropine eye drops, although compromising AA to some extent, for slowing myopia progression without interfering with exotropia conditions or binocular vision in children with myopia and IXT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>Chinese Clinical Trial Registry Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/showprojEN.html?proj=63725\">ChiCTR2000039827<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.2295","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:09:34Z","timestamp":1720019374000},"page":"722","source":"Crossref","is-referenced-by-count":31,"title":["0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia"],"prefix":"10.1001","volume":"142","author":[{"given":"Zijin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medical Technology, Jiangsu College of Nursing, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi240034r1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ophtha.2004.07.033","article-title":"Incidence and types of childhood exotropia: a population-based study.","volume":"112","author":"Govindan","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi240034r2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055112","article-title":"Prevalence of strabismus among preschool children in eastern China and comparison at a 5-year interval: a population-based cross-sectional study.","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"eoi240034r3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ajo.2006.06.053","article-title":"Factors associated with a previous diagnosis of strabismus in a population-based sample of 12-year-old Australian children.","volume":"142","author":"Robaei","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi240034r4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.ophtha.2011.06.032","article-title":"Risk factors associated with childhood strabismus: the multiethnic pediatric eye disease and Baltimore pediatric eye disease studies.","volume":"118","author":"Cotter","year":"2011","journal-title":"Ophthalmology"},{"key":"eoi240034r6","doi-asserted-by":"publisher","first-page":"35177","DOI":"10.1038\/srep35177","article-title":"Refractive errors and concomitant strabismus: a systematic review and meta-analysis.","volume":"6","author":"Tang","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"eoi240034r7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ajo.2009.10.009","article-title":"The development of myopia among children with intermittent exotropia.","volume":"149","author":"Ekdawi","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi240034r8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajo.2012.05.026","article-title":"Binocular visual acuity in intermittent exotropia: role of accommodative convergence.","volume":"154","author":"Ahn","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi240034r9","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/aos.2012.90.issue-2","article-title":"Evidence that convergence rather than accommodation controls intermittent distance exotropia.","volume":"90","author":"Horwood","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"eoi240034r10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ophtha.2019.01.015","article-title":"Three-year observation of children 3 to 10 years of age with untreated intermittent exotropia.","volume":"126","author":"Mohney","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi240034r11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/opo.v40.2","article-title":"Three-year observation of children 12 to 35 months old with untreated intermittent exotropia.","volume":"40","author":"Cotter","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"eoi240034r12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control.","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi240034r13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi240034r14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on Atropine for the Treatment of Myopia 2: myopia control with atropine 0.01% eye drops.","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240034r15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control.","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi240034r16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 2 report.","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi240034r17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued vs washout: phase 3 report.","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi240034r18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/09273970600894716","article-title":"An office-based scale for assessing control in intermittent exotropia.","volume":"14","author":"Mohney","year":"2006","journal-title":"Strabismus"},{"key":"eoi240034r19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajo.2023.02.024","article-title":"Preoperative and postoperative clinical factors in predicting the early recurrence risk of intermittent exotropia after surgery.","volume":"251","author":"Wang","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi240034r20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/OPX.0000000000000251","article-title":"Squinting and photophobia in intermittent exotropia.","volume":"91","author":"Oh","year":"2014","journal-title":"Optom Vis Sci"},{"issue":"3","key":"eoi240034r21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis.","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240034r22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents: a 5-year study of safety and effectiveness.","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"11","key":"eoi240034r23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eye drops for the treatment of myopia progression in Chinese children: a randomized clinical trial.","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"eoi240034r24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/bjophthalmol-2019-315440","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter, and accommodative amplitude: low-dose atropine and myopia progression.","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi240034r25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"eoi240034r26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10792-020-01658-0","article-title":"Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children.","volume":"41","author":"Zhao","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"9","key":"eoi240034r27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: multicentric randomized trial.","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi240034r28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and Safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial.","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"eoi240034r29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","article-title":"Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-Concentration Atropine for Myopia Progression study.","volume":"128","author":"Li","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi240034r30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study.","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi240034r31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/jop.2022.0036","article-title":"Factors related to axial length elongation in myopic children who received 0.05% atropine treatment.","volume":"38","author":"Cho","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"eoi240034r32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren.","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"eoi240034r33","first-page":"2297","article-title":"Polymorphisms in steroidogenesis genes, sex steroid levels, and high myopia in the Taiwanese population.","volume":"17","author":"Chen","year":"2011","journal-title":"Mol Vis"},{"issue":"1","key":"eoi240034r34","doi-asserted-by":"publisher","first-page":"17344","DOI":"10.1038\/s41598-021-96698-6","article-title":"Stepwise low concentration atropine for myopic control: a 10-year cohort study.","volume":"11","author":"Chuang","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"eoi240034r35","doi-asserted-by":"publisher","first-page":"11729","DOI":"10.1038\/s41598-021-88719-1","article-title":"Risk factors for rapid axial length elongation with low concentration atropine for myopia control.","volume":"11","author":"Fu","year":"2021","journal-title":"Sci Rep"},{"key":"eoi240034r36","doi-asserted-by":"publisher","first-page":"01081","DOI":"10.3389\/fphar.2020.01081","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control.","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"eoi240034r37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4103\/ijo.IJO_1243_19","article-title":"Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia.","volume":"68","author":"Kothari","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"eoi240034r38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00006324-195101000-00003","article-title":"Accommodative-convergence in presbyopia.","volume":"28","author":"Morgan","year":"1951","journal-title":"Am J Optom Arch Am Acad Optom"},{"issue":"13","key":"eoi240034r39","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1177\/1535370216640931","article-title":"Cytotoxicity of atropine to human corneal endothelial cells by inducing mitochondrion-dependent apoptosis.","volume":"241","author":"Wen","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"eoi240034r40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1159\/000510779","article-title":"Combined orthokeratology with atropine for children with myopia: a meta-analysis.","volume":"64","author":"Wang","year":"2021","journal-title":"Ophthalmic Res"},{"issue":"1","key":"eoi240034r41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12886-022-02561-1","article-title":"Corneal endothelial cell density and its correlation with birth weight, anthropometric parameters, and ocular biometric parameters in Chinese school children.","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"eoi240034r43","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.ophtha.2014.07.021","article-title":"A randomized trial comparing part-time patching with observation for children 3 to 10 years of age with intermittent exotropia.","volume":"121","author":"Cotter","year":"2014","journal-title":"Ophthalmology"},{"key":"eoi240034r5","volume-title":"An Essay on the Nature and the Consequences of Anomalies of Refraction (1899)","author":"Donders","year":"2008"},{"key":"eoi240034r42","author":"Geronimi","year":"2015"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2820256\/jamaophthalmology_wang_2024_oi_240034_1723584463.24826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:02:22Z","timestamp":1723734142000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2820256"}},"subtitle":["The AMIXT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2295","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}